iRegene doses first US Parkinson’s patient, launches landmark MSA trial in China

The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration

Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years

Morepen Labs lands record Rs. 825 crore global CDMO contract

This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major

FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg

Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension

Ind-Swift Labs to pump Rs. 40 crore into Samba facility for global expansion

The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability

EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder

The recommendation is based on new data from continuous safety monitoring of medicines in the EU

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise